Skip to main content
Fig. 3 | Journal of Nanobiotechnology

Fig. 3

From: Peripheral administration of nanomicelle-encapsulated anti-Aβ oligomer fragment antibody reduces various toxic Aβ species in the brain

Fig. 3

Comparative efficacies of the administration of various anti-Aβ Fabs. A The three-day hidden platform test of the AD model mice was performed after 10 weeks of PBS administration in anti-amyloid β oligomer (AβO) 6H4 Fabs encapsulated in the PMs, anti-Aβ 3D6 Fabs encapsulated in the PMs, and anti-AβO 6H4 Fabs. The 6H4 Fab PM group (black squares) required significantly shorter times to reach the platform compared with the PBS group (gray circles) on days 2 and 3. Those in the 3D6 Fab PM (black triangles) and 6H4 Fab (gray reverse triangles) groups showed no significant differences compared with the PBS group. B The 6H4 Fab PM group (black bars) stayed for the longest time in the platform quarter area in the water maze test, and the difference was significant. C No significant difference was observed among the groups in the spontaneous alternation rate in the Y-maze test. Values are expressed as the mean ± standard error of the mean. Two-way analysis of variance (ANOVA) with Dunnett's post hoc test was performed in A and one-way ANOVA with Dunnett's post hoc test in B, C. *p < 0.05, **p < 0.01. amyloid β, Fab antibody fragment, PBS phosphate-buffered saline, PM polymeric nanomicelle, WT wild type

Back to article page